Please assess the completion status of the following clinical trial:

Trial Title: A Trial to Compare Oxaliplatin, Folinic Acid (FA) and 5-Fluorouracil (5FU) Combination Chemotherapy (FOLFOX-4) With or Without Cetuximab in the 1st Line Treatment of Metastatic Colorectal Cancer (mCRC) in Chinese Rat Sarcoma Viral Oncogene Homolog (RAS) Wild-type Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written informed consent (first and second)~* Chinese with Chinese citizenship~* Male or female subjects greater than or equal to (\>=) 18 years of age~* Medically accepted effective contraception if procreative potential exists (applicable for both male and female subjects until at least 90 days after the last dose of trial treatment)~* Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum~* First occurrence of metastatic disease (not curatively resectable) RAS wild-type status in tumor tissue~* At least one measurable lesion by computer tomography (CT) or magnetic resonance imaging (MRI) according to RECIST (not in an irradiated area)~* Life expectancy of at least 12 weeks~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at trial entry~* White blood cell count \>= 3 × 10x9/L with neutrophils \>= 1.5 × 10x9/L, platelet count \>= 100 × 10x9/L and hemoglobin \>= 6.21 mmol/L (10 g/dL)~* Total bilirubin \<= 1.5 × upper limit of reference range~* Aspartate transaminase (AST) and alanine transaminase (ALT) \<= 2.5 × upper limit of reference range or \<= 5 × upper reference range in subjects with liver metastasis~* Serum creatinine \<= 1.5 × upper limit of reference range~* Recovery from relevant toxicity due to previous treatment before trial entry~Exclusion Criteria:~* Previous chemotherapy for CRC except adjuvant treatment if terminated \> 9 months (oxaliplatin-based chemotherapy) or \> 6 months (non-oxaliplatin-based chemotherapy) before the start of treatment in this trial~* Radiotherapy or surgery (excluding prior diagnostic biopsy) in the 30 days before trial treatment~* Previous treatment with monoclonal antibody therapy, vascular endothelial growth factor (VEGF) pathway-targeting therapy, epidermal growth factor receptor (EGFR) pathway-targeting therapy, or other signal transduction inhibitors~* History of organ allograft, autologous stem cell transplantation, or allogeneic stem cell transplantation~* Renal replacement therapy~* Intake of any investigational medication within 30 days before trial entry~* Concurrent chronic systemic immune therapy or hormone therapy except physiologic replacement~* Granulocyte colony stimulating factor (G-CSF) or granulocyte macrophage colony stimulating factor (GM-CSF) within 3 weeks of trial entry (these growth factors may be used during the trial thereafter)~* Other non-permitted concomitant anticancer therapies~* Known brain metastasis and/or leptomeningeal disease. Subjects with neurological symptoms should undergo a CT scan/MRI of the brain to exclude brain metastasis~* Previous malignancy other than CRC in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix~* Clinically significant cardiovascular disease, e.g. cardiac failure of New York Heart Association classes III-IV, uncontrolled coronary artery disease, cardiomyopathy, uncontrolled arrhythmia, uncontrolled hypertension, or history of myocardial infarction in the last 5 years, or left ventricular ejection fraction below the institutional range of normal on a baseline multiple gated acquisition scan or echocardiogram~* Acute or sub-acute intestinal occlusion or history of inflammatory bowel disease~* Active clinically serious infections (\> grade 2 National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0), including active tuberculosis~* Known and declared history of human immunodeficiency virus (HIV) infection or chronic hepatitis B or C~* Peripheral neuropathy \> grade 1~* Signs and symptoms suggestive of transmissible spongiform encephalopathy, or family members who suffer(ed) from such~* Uncontrolled diabetes mellitus, pulmonary fibrosis, acute pulmonary disorder, interstitial pneumonia, or liver failure~* Known hypersensitivity or allergic reactions against any of the components of the trial treatments~* Pregnancy (absence to be confirmed by serum β-human chorionic gonadotropin test) or breastfeeding~* Ongoing alcohol or drug abuse~* Presence of a medical or psychological condition that would not permit the subject to complete the trial or sign informed consent~* Participation in another clinical trial within the past 30 days~* Other significant disease that in the investigator's opinion should exclude the subject from the trial~* Legal incapacity or limited legal capacity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cetuximab + FOLFOX-4 (Type: EXPERIMENTAL): Subjects received cetuximab in combination with FOLFOX-4 chemotherapy regimen. FOLFOX-4 chemotherapy regimen consists of a combination of oxaliplatin with 5-fluorouracil (5-FU)/folinic acid (FA). Cetuximab was always administered every 7 days with an initial dose of 400 milligram per square meter (mg/m\^2) at 5 milligram per minute (mg/min) and 250 mg/m\^2 at 10 mg/min for subsequent infusions, followed by oxaliplatin 85 mg/m\^2 infused over 120 minutes at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin, FA was administered at a dose of 200 mg/m\^2 infused over 120 minutes, on Day 1, Day 2, and every 2 weeks and then 5- FU was administered as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infused over 22 hours, on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.
- FOLFOX-4 (Type: ACTIVE_COMPARATOR): Subjects received FOLFOX-4 chemotherapy regimen that consists of a combination of oxaliplatin with 5-FU/FA. Oxaliplatin 85 mg/m\^2 infused over 120 minutes was administered first or simultaneously with FA at a dose of 200 mg/m\^2 infused over 120 minutes on Day 1, Day 2, and every 2 weeks and then 5-FU was administered as a bolus of 400 mg/m\^2/day intravenously over 2-4 minutes followed by 600 mg/m\^2/day infused over 22 hours on Day 1, Day 2, and every 2 weeks. All subjects received treatment until progression of disease, withdrawal of consent, or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).